Many dialysis patients are fluid overloaded or hypervolemic, which can lead to hypertension1, left ventricular hypertrophy2, and congestive heart failure3. Cardiovascular strain can be a consequence of interdialytic weight gain, chronic fluid overload and inappropriate fluid removal during hemodialysis4,5. Fluid overload is associated with hemodynamic instability and higher cardiovascular morbidity6,7. As such, fluid management and the achievement of a normal hydration status or euvolemia is important.

Accurate, real-time fluid management with Crit-Line® technology allows the clinician insight as to how a patient is tolerating dialysis throughout a treatment. Adjusting ultrafiltration rates and maximizing the amount of fluid removal, while minimizing the potential for hypovolemic and intradialytic symptoms, is critical to a more effective dialysis treatment. Crit-Line technology allows the clinician to do just that. The clinician has the ability to visualize treatments in real-time and to understand how the patient is tolerating their treatment.

Crit-Line Technology:

  • Provides insight as to how a patient is tolerating dialysis.
  • Provides the clinician with data that may help remove the maximum amount of fluid while preventing common symptoms of dialysis (nausea, cramping and vomiting).
  • Provides a more effective treatment for dialysis patients and clinicians.
  • Provides data to help identify patients that may be at risk for intradialytic symptoms.
  • Helps the healthcare professional visualize the patient's plasma refill rate in real-time.
  • Helps the healthcare professional maximize fluid removal while minimizing the potential for hypovolemic symptoms. 

Crit-Line technology is a cost-effective method to continuously monitor key blood parameters during therapy allowing the clinician to determine appropriate intervention, if needed, during treatment.

Watch our video on monitoring blood volume using Crit-Line Technology.  
 

  1. Dionisio P, et al. Influence of the hydration state on blood pressure values in a group of patients on regular maintenance hemodialysis Blood Purif. 1997; 15:25-33 
  2. Stegmayr BG. Ultrafiltation and dry weight – what are the cardiovascular effects? Artif Organs 2003; 27:227-229 
  3. Harnett JD, et al. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors Kidney Int. 1995; 47:884-890 
  4. Kalantar-Zadeh K, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009; 119(5):671–679 
  5. Wizemann V, et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant. 2009; 24(5):1574–1579 
  6. Jacobs LH, et al. Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. Nephrol Dial Transplant. 2010; 25(1):243–248.
  7. David S, et al. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant. 2008; 23(4):1370–1377

 

Caution: Federal (US) law restricts these devices to sale by or on the order of a physician.

Note: Read the Instructions for Use for safe and proper use of these devices. For a complete description of hazards, contraindications, side effects and precautions, see full package labeling.

© 2017, 2019, Fresenius Medical Care. All Rights Re­served. Fresenius Medical Care, the triangle logo, 2008, BlueStar, Crit-Line and CLiC are trademarks of Fresenius Medical Care Hold­ings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners. P/N 102249-01 Rev E 07/2019